Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results

IF 4.9 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Atherosclerosis Pub Date : 2024-08-15 DOI:10.1016/j.atherosclerosis.2024.118459

Daniel Gaudet, Denes Pall, Gerald Watts, Stephen Nicholls, Robert Rosenson, Karen Modesto, Ting Chang, Stacey Melquist, Ran Fu, Ma'An Muhsin, Javier San Martin, Christie Ballantyne

引用次数: 0

查看原文本刊更多论文

研究性 RNAI 疗法 Plozasiran（ARO-APOC3）在严重高甘油三酯血症 (SHTG) 患者中的 APOC-3 和甘油三酯 (TG) 中显示出深远而持久的降低效果，SHASTA-2 最终结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis 医学-外周血管病

CiteScore

9.80

自引率

3.80%

发文量

1269

审稿时长

36 days

期刊介绍： Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.